Patients who had end-stage renal disease secondary to amyloidosis had poorer survival rates compared with patients with kidney disease secondary to other causes. Amyloidosis may impact long-term ...

The type of ATTR you have and how early it was diagnosed are two factors that can affect the prognosis of your disease.

Four hundred and fifty-seven (n=457) consecutive patients newly diagnosed with AL amyloidosis who underwent ASCT as their first-line treatment between 1 January 2000 and 31 August 2015 were included ...

CLEVELAND, Ohio – First-line treatment with the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals) plus dexamethasone and an alkylating agent (BDex+AA) improves survival in patients ...

A new staging system developed with a more accessible test to predict the chance of survival in patients living with light chain (AL) amyloidosis. A new staging system developed with a more accessible ...

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation ...

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...

PURPOSE: Based on the success of hematopoietic stem-cell transplantation (HSCT) for multiple myeloma, HSCT is being used to treat patients with primary systemic amyloidosis (AL). This article ...

In the largest study of its kind, researchers have found that HDM/SCT produces prolonged survival with improved safety in patients with AL amyloidosis. Additionally, they have for the first time ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...